WO2001007070A1 - Method for measuring coagulant factor activity in whole blood - Google Patents
Method for measuring coagulant factor activity in whole blood Download PDFInfo
- Publication number
- WO2001007070A1 WO2001007070A1 PCT/US2000/020118 US0020118W WO0107070A1 WO 2001007070 A1 WO2001007070 A1 WO 2001007070A1 US 0020118 W US0020118 W US 0020118W WO 0107070 A1 WO0107070 A1 WO 0107070A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitor
- whole blood
- blood
- sample
- factor
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
Definitions
- disease prevention More specifically, it relates to diagnostic methods and test kits for
- risk for clot formation would help rule in or rule out thrombotic events and
- Blood may also clot too slowly, or not at all, which can lead to bleeding or
- hemophilias are examples of inheritable
- hemophilia A The best known of the inherited disorders of coagulation are hemophilia A and
- hemophilia may not be evident until later in life.
- Treatment of hemophilias generally consists of transfusions of concentrates of
- DIC Disseminated intravascular coagulation
- Blood clotting is a complex process involving multiple initiators, cascades of
- insoluble fibrin strands or a clot For example, clot formation may be detected
- the measurement of clotting time may be made immediately on freshly drawn
- blood without added anticoagulants can be used without added anticoagulants.
- the clotting time measurement is initiated by adding a calcium salt to reverse the effect of the
- PT PT
- APTT activated partial thromboplastin time
- thrombotic event also may be performed by measuring the level of soluble fibrin or
- warfarin would be improved if the coagulability of whole blood, rather than plasma
- anticoagulants modulates coagulability through cellular as well as soluble (plasma)
- tissue plasminogen activator protein a procoagulant protein called tissue
- Factor III also known as Factor III, which is a transmembrane glycoprotein present on the
- monocytes surface of circulating cell known as monocytes. Tissue factor is also found in
- tissue factor has been found on circulating cells and vesicles in plasma from
- the level of tissue factor activity in whole blood is a diagnostically useful
- Tissue factor must form an active complex with a plasma clotting factor
- prothrombinase complex active procoagulant
- thrombin cleaves fibrinogen to produce fibrin, which forms a clot.
- modified recalcification time is measured for a blood sample.
- immunomodulator creates a condition that simulates disease or trauma, thus
- present invention provides another important assessment of tissue factor by providing
- TF tissue factor pathway inhibitor
- plasma can be determined by the degree of correction obtained when the plasma is
- the patient's plasma is compared to the correction obtained by known concentrations
- hypocoagulability i.e. pathologically slow blood clotting
- coagulation cascade such as F 1.2 prothrombin fragment, D-dimer, soluble fibrin and
- the present invention provides a method to rapidly assess the overall
- the sample is whole blood
- the resulting clotting time represents the overall coagulant
- Figure 1 is a diagram showing the central role of monocyte TF during the
- Thrombin activates platelets, which form a thrombogenic surface for the prothrombinase complex (Xa: Va). Fibrinogen is
- Figure 2 shows the detection of exogenously added TF in whole blood through
- Figure 3 shows the effect of anti-TF antibodies on re-calcified whole blood
- anti-TF antibodies blocked the LPS-mediated reduction in the re-calcified whole
- Figure 4 shows the effect of recombinant TF on the re-calcified whole blood
- Figure 5a shows the clotting times for cells isolated from blood and mixed
- Figure 5b shows the effect of an inhibitory anti-Factor XI antibody (100
- Figure 5c shows the effect of corn trypsin inhibitor (CTI) (32 ⁇ g/mL) added to
- Figure 6a shows the effect of unfractionated heparin (0-0.1 U/ml) on the
- Figure 6b shows the effect of low molecular weight heparin (LMWH; 0-0.25
- Figure 6c shows the effect of hirudin (0-0.1 U/ml) on the clotting time of LPS-
- Figure 7 compares the re-calcified whole blood clotting times of patients with
- heart attack for example, stroke, coronary artery disease, deep vein thrombosis, and
- erythematosus, and infection may predispose patients to undergo adverse clotting
- prothrombotic pathways to predominate and intensify, as compared with the
- the soluble (plasma) portion of blood as well as that provided by the cellular portion.
- prothrombin Traditional measures of clotting or blood coagulability, for example, prothrombin
- PT active partial thromboplastin time
- APTT active partial thromboplastin time
- example is the contribution of tissue factor to blood coagulability. As described
- tissue factor is an initiator and modulator of blood coagulation, and may be
- Elevated levels are associated with pathologic states.
- pathologic states present in the blood. Elevated levels are associated with pathologic states.
- tissue factor other components present in or on the cellular components of blood may also modulate blood coagulability and also contribute to the propensity for blood
- the method of the invention involves measuring whole
- tissue factor in contrast to the above-mentioned modified recalcif ⁇ cation time test
- tissue factor which in turn influences the coagulant
- the method of the present invention does not measure
- the method of the present invention may be performed with fresh whole
- a blood sample may be collected in the presence of an anticoagulant
- the anticoagulant will block the
- the inhibitor may be added, and then
- the anticoagulant in the blood sample must be reversed at the time that blood
- coagulability or clotting time is measured. This is accomplished by the addition of a
- reactivate the clotting process is referred to as the recalcification time.
- Any inhibitor of a procoagulant or anticoagulant is suitable for use in the
- Suitable inhibitors include, among other things, antibodies or
- the analogue is a peptide.
- Suitable inhibitors are known to those skilled
- tissue factor exhibiting sufficient affinity for tissue factor may be used as the inhibitor of TF:Factor
- VD10 and VIC 12 are antibodies to VD10 and VIC 12 are antigens.
- the concentration of the antibody or combination of antibodies in the reagent is provided so that it may be easily added to the blood sample to
- the inhibitor is Factor VIlai, which is a
- Determination of clotting time by the methods of the invention may also be
- modulators of the clotting process contemplated for use in the present invention
- procoagulants such as thrombin, platelet activating factor, fibrinogen, kaolin,
- anticoagulant activity useful as modulators of the clotting process of the present
- inventions include protein C, protein S, antithrombin III, thrombomodulin, tissue
- coagulant activity of blood may also be used as modulators in the invention.
- cancer cell extracts and amniotic fluid may serve as modulators.
- the invention is not limited to any particular method of measuring clotting.
- reagents that initiate clotting or affect clotting times may be
- TEG thrombelastograph
- CTEG computerized thrombelastograph
- SONOCLOTTM and CTEG are capable of recording changes in the coagulation
- HEMOCHRONTM system International Technidyne Corp., which uses a precision
- the assays may be performed directly with a fresh blood sample.
- the necessary reagents, such as an antibody, may be preloaded into the coagulation
- the blood is first collected with an
- anticoagulant that binds calcium ions, such as citrate, oxalate, EDTA, etc., and the
- anticoagulants may result when blood collection is performed in the presence of a
- milliliter of citrated blood is prepared with control antibody or protein control.
- control versus the sample containing inhibitor (antibody) is used diagnostically to
- a test kit is provided for determining
- Tissue factor also known as Factor III, is responsible for initiating the Tissue factor
- Tissue factor is primarily present in the monocytes of
- Certain disease states may predispose a person's monocytes to be
- the present invention may be used to assess hypercoagulability by detecting
- tissue factor whole blood assay described in this example involves a test
- Control vial + high positive TF control 250 to 350 seconds
- Control vial + low positive TF control 650 to 750 seconds
- Figure 2 shows the detection of exogenously added TF
- This example describes a lipopolysaccharide-stimulation test procedure on the
- Hemochron instrument that assesses the production of TF in whole blood in response
- citrate/CTI blood collection tubes provided in the kit. Blood should be analyzed
- tissue factor whole blood assay described in this example involves a test
- CTI com trypsin inhibitor
- the Vacutainer tube should contain at least 4.5 ml of
- Vials are color-coded by their cap: either a clear cap (for control mAb), a
- patient sample will require four tubes, one of each color. Store at 2-8° C.
- Tissue factor monoclonal antibody in tris buffered saline (pH 7.4) 1 mg/ml BSA.
- Sample preparation Place one clear vial, one white vial, one yellow vial, and one
- Analyzer automatically calculates the clotting time. The test should be allowed to run for at least 20 minutes to obtain additional raw data, even though the tone will
- vial type (clear, white, yellow, or blue) patient
- sources of error for each group include:
- Blood donor subjects were drawn from a healthy, normal population of the
- NNSA nonsteroidal anti-inflammatory drags
- SonoclotTM Coagulation and Platelet Function Analyzer (Sienco, Inc., Wheat Ridge,
- the clotting time is derived by
- LPS lipopolysaccharide
- Inhibitory anti-human TF monoclonal antibodies significantly prolonged the clotting
- Factor Vll-deficient plasma may be due to differences between fresh plasma versus
- an inhibitory anti-Factor Xla antibody significantly prolonged the clotting
- heparin shows greater antithrombin activity relative to its anti-Factor Xa activity (5).
- the LMWHs have antithrombin activity that is low, compared with their
- Hirudin selectively inhibits thrombin (6).
- LPS-stimulated blood prolonged the clotting times in a dose-dependent manner.
- thrombosis potential differences between bivalirudin and hirudin. Am. J.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00950617A EP1212073A4 (en) | 1999-07-23 | 2000-07-24 | Method for measuring coagulant factor activity in whole blood |
CA002378898A CA2378898A1 (en) | 1999-07-23 | 2000-07-24 | Method for measuring coagulant factor activity in whole blood |
AU63697/00A AU6369700A (en) | 1999-07-23 | 2000-07-24 | Method for measuring coagulant factor activity in whole blood |
JP2001511953A JP2003505678A (en) | 1999-07-23 | 2000-07-24 | Method for measuring coagulation factor activity in whole blood |
KR1020027000975A KR20020042622A (en) | 1999-07-23 | 2000-07-24 | Method for measuring coagulant factor activity in whole blood |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14514099P | 1999-07-23 | 1999-07-23 | |
US60/145,140 | 1999-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001007070A1 true WO2001007070A1 (en) | 2001-02-01 |
Family
ID=22511767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/020118 WO2001007070A1 (en) | 1999-07-23 | 2000-07-24 | Method for measuring coagulant factor activity in whole blood |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1212073A4 (en) |
JP (1) | JP2003505678A (en) |
KR (1) | KR20020042622A (en) |
CN (1) | CN1368886A (en) |
AU (1) | AU6369700A (en) |
CA (1) | CA2378898A1 (en) |
WO (1) | WO2001007070A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002079375A1 (en) * | 2001-03-30 | 2002-10-10 | Coagulation Diagnostics, Incorporated | Rapid assessment of coagulation activity in whole blood |
EP1337660A2 (en) * | 2000-10-27 | 2003-08-27 | BioMerieux, Inc. | Method of determining global coagulability and hemostatic potential |
WO2006084648A1 (en) | 2005-02-08 | 2006-08-17 | Csl Behring Gmbh | Method for differentiating a xiii factor and fibrinogen deficiency states by means of thrombelastographic engineering |
US8574849B2 (en) | 2007-10-03 | 2013-11-05 | The University Of Vermont And State Agriculture College | Methods of detection of factor XIa and tissue factor |
US8962563B2 (en) | 2009-12-21 | 2015-02-24 | Baxter International, Inc. | TFPI inhibitors and methods of use |
US9018167B2 (en) | 2010-03-19 | 2015-04-28 | Baxter International Inc. | TFPI inhibitors and methods of use |
US9777051B2 (en) | 2008-12-19 | 2017-10-03 | Baxalta GmbH | TFPI inhibitors and methods of use |
US10337048B2 (en) | 2013-06-28 | 2019-07-02 | Roche Diagnostics Operations, Inc. | Methods for universal determination of anticoagulant activity |
RU2750839C1 (en) * | 2020-05-18 | 2021-07-05 | Общество с ограниченной ответственностью "Меднорд-Техника" (ООО "Меднорд-Т") | Apparatus and method for express estimation of aggregative activity of formed elements of blood |
US11650196B2 (en) | 2017-01-06 | 2023-05-16 | Sony Corporation | Blood coagulation system analysis apparatus, blood coagulation system analysis system, blood coagulation system analysis method, blood coagulation system analysis program, blood loss prediction apparatus, blood loss prediction system, blood loss prediction method, and blood loss prediction program |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4267592B2 (en) | 2005-05-23 | 2009-05-27 | 潤 川崎 | Antithrombotic drug efficacy test method |
CN100434901C (en) * | 2006-01-12 | 2008-11-19 | 上海交通大学 | Teaching kit for hemoglobin gel chromatography |
US20090004673A1 (en) * | 2006-01-31 | 2009-01-01 | Mitsubishi Kagaku Iatron, Inc. | Method for Determining Condition of Disseminated Intravascular Coagulation |
GB0701821D0 (en) * | 2007-02-01 | 2007-03-14 | Pentapharm Ag | Diagnostic composition and its use in the determination of coagulation characteristics of a test liquid |
EP2471945A1 (en) * | 2010-12-30 | 2012-07-04 | Siemens Healthcare Diagnostics Products GmbH | Method for determining coagulation inhibitors |
RU2682622C2 (en) * | 2012-10-25 | 2019-03-19 | Конинклейке Филипс Н.В. | Combined use of clinical risk factors and molecular markers of thrombosis for clinical decision support |
LT2946206T (en) | 2013-01-20 | 2019-04-25 | Dyax Corp. | Evaluation, assays and treatment of pkal-mediated disorders |
CN103604766A (en) * | 2013-11-25 | 2014-02-26 | 牡丹江友搏药业股份有限公司 | Biological quality control method of Shuxuetong injection |
US9452199B2 (en) | 2014-01-17 | 2016-09-27 | General Electric Company | Platelet activation and growth factor release using electric pulses |
SE540132C2 (en) * | 2014-05-22 | 2018-04-10 | Zafena Ab | Method of analysis for the determination of anticoagulants in blood or blood plasma |
CN104345154B (en) * | 2014-08-22 | 2016-10-26 | 北京蛋白质组研究中心 | A kind of double-antibody sandwich test kit detecting many tumors relevant " the box-like mark of polypeptide-protein groups " |
CN104177503B (en) * | 2014-08-22 | 2018-04-13 | 北京蛋白质组研究中心 | A kind of related " polypeptide protein combined type " marker of kinase pathway and quantitative measurement technology |
CN104698159B (en) * | 2015-03-10 | 2017-03-08 | 中国科学院苏州生物医学工程技术研究所 | A kind of detection method of endotoxin content |
US20210263052A1 (en) * | 2018-07-25 | 2021-08-26 | Sony Corporation | Blood coagulation system analysis device |
CN113906295A (en) * | 2019-03-15 | 2022-01-07 | 考爱古莱森科技有限责任公司 | Coagulation test devices, systems, and methods of use |
US10429377B1 (en) | 2019-03-15 | 2019-10-01 | Coagulation Sciences Llc | Coagulation test device, system, and method of use |
CN114402200A (en) | 2019-04-16 | 2022-04-26 | 武田药品工业株式会社 | Method for quantifying functional C1 esterase inhibitor (FC1-INH) |
WO2022145475A1 (en) * | 2020-12-28 | 2022-07-07 | 藤森工業株式会社 | Method for evaluating blood coagulation performance, and method for inspecting risk of thrombosis |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4882272A (en) * | 1986-10-01 | 1989-11-21 | Temple University - Of The Commonwealth System Of Higher Education | High molecular weight kininogen assay |
US5783447A (en) * | 1996-10-02 | 1998-07-21 | University Of Medicine And Dentistry Of New Jersey | Hypercoagulability comparative determinants obtained using detection systems with variable force-induced energy inputs |
WO1999064622A1 (en) * | 1998-06-08 | 1999-12-16 | University Of Vermont And State Agriculture College | Inhibition of coagulation in blood and blood products |
US6107280A (en) * | 1996-05-10 | 2000-08-22 | Xoma Corporation | Antithrombotic materials and methods |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4814247A (en) * | 1983-01-26 | 1989-03-21 | University Of Medicine And Dentistry Of New Jersey | Method for determining the existance and/or the monitoring of a pathological condition in a mammal |
-
2000
- 2000-07-24 JP JP2001511953A patent/JP2003505678A/en active Pending
- 2000-07-24 EP EP00950617A patent/EP1212073A4/en not_active Withdrawn
- 2000-07-24 CN CN00810751A patent/CN1368886A/en active Pending
- 2000-07-24 KR KR1020027000975A patent/KR20020042622A/en not_active Application Discontinuation
- 2000-07-24 AU AU63697/00A patent/AU6369700A/en not_active Abandoned
- 2000-07-24 WO PCT/US2000/020118 patent/WO2001007070A1/en not_active Application Discontinuation
- 2000-07-24 CA CA002378898A patent/CA2378898A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4882272A (en) * | 1986-10-01 | 1989-11-21 | Temple University - Of The Commonwealth System Of Higher Education | High molecular weight kininogen assay |
US6107280A (en) * | 1996-05-10 | 2000-08-22 | Xoma Corporation | Antithrombotic materials and methods |
US5783447A (en) * | 1996-10-02 | 1998-07-21 | University Of Medicine And Dentistry Of New Jersey | Hypercoagulability comparative determinants obtained using detection systems with variable force-induced energy inputs |
WO1999064622A1 (en) * | 1998-06-08 | 1999-12-16 | University Of Vermont And State Agriculture College | Inhibition of coagulation in blood and blood products |
Non-Patent Citations (1)
Title |
---|
See also references of EP1212073A4 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1337660A2 (en) * | 2000-10-27 | 2003-08-27 | BioMerieux, Inc. | Method of determining global coagulability and hemostatic potential |
EP1337660A4 (en) * | 2000-10-27 | 2005-08-17 | Bio Merieux Inc | Method of determining global coagulability and hemostatic potential |
WO2002079375A1 (en) * | 2001-03-30 | 2002-10-10 | Coagulation Diagnostics, Incorporated | Rapid assessment of coagulation activity in whole blood |
WO2006084648A1 (en) | 2005-02-08 | 2006-08-17 | Csl Behring Gmbh | Method for differentiating a xiii factor and fibrinogen deficiency states by means of thrombelastographic engineering |
AU2006212471B2 (en) * | 2005-02-08 | 2011-02-24 | Wolfgang Korte | Method for differentiating a XIII factor and fibrinogen deficiency states by means of thrombelastographic engineering |
US7939288B2 (en) | 2005-02-08 | 2011-05-10 | Csl Behring Gmbh | Method for differentiating between factor XIII deficiency states and fibrinogen deficiency states by means of thrombelastographic techniques |
US8574849B2 (en) | 2007-10-03 | 2013-11-05 | The University Of Vermont And State Agriculture College | Methods of detection of factor XIa and tissue factor |
US9873720B2 (en) | 2008-12-19 | 2018-01-23 | Baxalta GmbH | TFPI inhibitors and methods of use |
US11001613B2 (en) | 2008-12-19 | 2021-05-11 | Takeda Pharmaceutical Company Limited | TFPI inhibitors and methods of use |
US9777051B2 (en) | 2008-12-19 | 2017-10-03 | Baxalta GmbH | TFPI inhibitors and methods of use |
US8962563B2 (en) | 2009-12-21 | 2015-02-24 | Baxter International, Inc. | TFPI inhibitors and methods of use |
US9018167B2 (en) | 2010-03-19 | 2015-04-28 | Baxter International Inc. | TFPI inhibitors and methods of use |
US10201586B2 (en) | 2010-03-19 | 2019-02-12 | Baxalta GmbH | TFPI inhibitors and methods of use |
US9556230B2 (en) | 2010-03-19 | 2017-01-31 | Baxalta GmbH | TFPI inhibitors and methods of use |
US11793855B2 (en) | 2010-03-19 | 2023-10-24 | Takeda Pharmaceutical Company Limited | TFPI inhibitors and methods of use |
US10800816B2 (en) | 2012-03-21 | 2020-10-13 | Baxalta GmbH | TFPI inhibitors and methods of use |
US10337048B2 (en) | 2013-06-28 | 2019-07-02 | Roche Diagnostics Operations, Inc. | Methods for universal determination of anticoagulant activity |
US11650196B2 (en) | 2017-01-06 | 2023-05-16 | Sony Corporation | Blood coagulation system analysis apparatus, blood coagulation system analysis system, blood coagulation system analysis method, blood coagulation system analysis program, blood loss prediction apparatus, blood loss prediction system, blood loss prediction method, and blood loss prediction program |
RU2750839C1 (en) * | 2020-05-18 | 2021-07-05 | Общество с ограниченной ответственностью "Меднорд-Техника" (ООО "Меднорд-Т") | Apparatus and method for express estimation of aggregative activity of formed elements of blood |
Also Published As
Publication number | Publication date |
---|---|
EP1212073A4 (en) | 2003-09-03 |
KR20020042622A (en) | 2002-06-05 |
AU6369700A (en) | 2001-02-13 |
CA2378898A1 (en) | 2001-02-01 |
CN1368886A (en) | 2002-09-11 |
JP2003505678A (en) | 2003-02-12 |
EP1212073A1 (en) | 2002-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001007070A1 (en) | Method for measuring coagulant factor activity in whole blood | |
US5525477A (en) | Method for diagnosing blood clotting disorders | |
Lowe et al. | Plasma fibrinogen | |
US6403381B1 (en) | Inhibition of coagulation in blood and blood products | |
Brummel‐Ziedins et al. | Thrombin generation: phenotypic quantitation | |
US20030064414A1 (en) | Rapid assessment of coagulation activity in whole blood | |
US6245573B1 (en) | Rapid assessment of the coagulant activity of blood | |
US5525478A (en) | Soluble thrombomodulin-based one-stage assay for vitamin-K dependent coagulation-inhibiting proteins | |
Lippi et al. | Milestones and perspectives in coagulation and hemostasis | |
CA2623142C (en) | Methods for a global assay of coagulation and fibrinolysis | |
EP2235542B1 (en) | Diagnostic in vitro method for assessing von willebrand disease and increased bleeding risk associated with von willebrand disease and acquired or congenital disorders of platelet function | |
Simpson et al. | Simultaneous thrombin and plasmin generation capacities in normal and abnormal states of coagulation and fibrinolysis in children and adults | |
JP3248621B2 (en) | Testing for thrombosis risk | |
CA2155503C (en) | A method for detecting defects in protein c/protein s mediated blood clotting | |
Hoffmann et al. | Automated nephelometry of fibrinogen: analytical performance and observations during thrombolytic therapy. | |
Laffan et al. | 17 Investigation of a thrombotic tendency | |
Cellai et al. | Assessment of fibrinolytic activity by measuring the lysis time of a tissue factor-induced clot: a feasibility evaluation | |
Ruberto et al. | Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk. | |
Johnston jr et al. | The fate of factor VII and Stuart factor during the clotting of normal blood | |
Kato et al. | Differences in the composition of activated partial thromboplastin time (APTT) reagents affect clot waveform analysis | |
US11630101B2 (en) | Method for diagnosing anomalies in the coagulation of blood | |
Herskovits et al. | Comparison of Russell viper venom–based and activated partial thromboplastin time–based screening assays for resistance to activated protein C | |
De Metz et al. | Use of a centrifugal analyzer for a chromogenic prothrombin time, a chromogenic activated partial thromboplastin time and a kinetic fibrinogen assay in a routine hospital laboratory | |
Wang et al. | Coagulation and Fibrinolysis | |
Laffan et al. | 16 Investigation of haemostasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 516584 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 63697/00 Country of ref document: AU Ref document number: 2378898 Country of ref document: CA Ref document number: IN/PCT/2002/00069/DE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008107513 Country of ref document: CN Ref document number: 1020027000975 Country of ref document: KR Ref document number: PA/A/2002/000861 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000950617 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027000975 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000950617 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000950617 Country of ref document: EP |